BTIG Research Upgrades ImmunityBio (NASDAQ:IBRX) to “Strong-Buy”

ImmunityBio (NASDAQ:IBRX) was upgraded by research analysts at BTIG Research to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also recently commented on the stock. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research report on Monday, February 23rd. HC Wainwright lifted their price target on ImmunityBio from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 price objective (up from $7.00) on shares of ImmunityBio in a research report on Wednesday, March 4th. Jefferies Financial Group upped their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of ImmunityBio in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $14.40.

ImmunityBio Stock Up 7.3%

IBRX opened at $8.39 on Wednesday. The stock has a market cap of $8.63 billion, a P/E ratio of -22.08 and a beta of -0.03. ImmunityBio has a 12 month low of $1.83 and a 12 month high of $12.43. The company has a fifty day simple moving average of $6.62 and a 200 day simple moving average of $3.82.

ImmunityBio (NASDAQ:IBRX) last posted its earnings results on Monday, March 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million during the quarter. On average, equities research analysts expect that ImmunityBio will post -0.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Christobel Selecky sold 50,000 shares of the firm’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $5.00, for a total transaction of $250,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Barry J. Simon sold 165,000 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $10.25, for a total transaction of $1,691,250.00. Following the completion of the sale, the director directly owned 2,925,821 shares of the company’s stock, valued at $29,989,665.25. The trade was a 5.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 501,967 shares of company stock worth $4,466,412 in the last 90 days. Corporate insiders own 69.48% of the company’s stock.

Hedge Funds Weigh In On ImmunityBio

Hedge funds and other institutional investors have recently modified their holdings of the business. Slow Capital Inc. purchased a new stake in shares of ImmunityBio during the third quarter valued at approximately $25,000. Truist Financial Corp purchased a new position in shares of ImmunityBio during the 3rd quarter valued at $27,000. Swiss Life Asset Management Ltd purchased a new stake in ImmunityBio in the 3rd quarter worth about $27,000. WealthPlan Investment Management LLC bought a new stake in ImmunityBio in the 4th quarter valued at about $27,000. Finally, Diversify Advisory Services LLC purchased a new stake in ImmunityBio during the second quarter valued at about $27,000. Hedge funds and other institutional investors own 8.58% of the company’s stock.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Anktiva approvals and sales growth are driving upside expectations — Zacks highlights recent approvals, growing U.S. uptake and global launches that set up a pivotal 2026 for Anktiva. IBRX Stock: Anktiva’s Approvals and What Comes Next
• Positive Sentiment: Company may benefit from a persistent BCG shortage that could accelerate Anktiva adoption in NMIBC; Zacks flags upcoming 2026 catalysts (FDA discussions, global launches, clinical milestones). IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
• Positive Sentiment: Operational progress: Benzinga reports ImmunityBio completed manufacturing engineering programs for its NK-cell therapy platform — a milestone that could ease scale-up and broaden pipeline value. Why Is ImmunityBio Stock Soaring On Friday?
• Positive Sentiment: Sell-side support: BTIG initiated coverage with a Buy and $13 price target, signaling analyst confidence in further upside from current levels. Benzinga
• Neutral Sentiment: Market narrative: MarketBeat/Barron’s coverage places ImmunityBio among small biotechs benefiting from powerful oncology launches (Anktiva), underscoring both growth potential and sector risk. Why 2 Small Biotechs May Hold the Key to New Cancer Treatments (IBRX)
• Negative Sentiment: Valuation and concentration risks: Zacks flags that the rally has pushed IBRX to roughly 33x sales for Anktiva and notes the premium assumes near-perfect commercialization; reliance on one product and a large 2025 net loss are key risk points. ImmunityBio Valuation: Paying 33x Sales for Anktiva

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.